Big Pharma is investing heavily in AI to slash development timelines and foster innovation. But instead of strengthening future relationships with the biotech world, the investment may position ...

As venture capitalists pull back on their funding for life sciences, Big Pharma is flexing its considerable financial muscle to grab up smaller biotech companies, providing an injection of ...